RT @ASBMR: The objective of a new #JBMR clinical trial was to evaluate the potential therapeutic advantage of Ca-Cit in comparison with calcium carbonate in HypoPT, on nephrolithiasis risk factors #ASBMR #openaccess #freetoread @WileyBiomedical https://t.co/zvEGs8Mggn https://t.co/tmSpGHaIvT


from Twitter https://twitter.com/GastonR48222321

June 30, 2022 at 08:15AM

Comentarios

Entradas más populares de este blog

Lunar iDXA